TL;DR
Get comfort and recovery gear delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
The Trump administration is backing increased research and potential legalization of ibogaine, a powerful psychedelic, to treat PTSD and opioid addiction. This marks a shift in drug policy and bipartisan interest in psychedelics.
The Trump administration has officially taken steps to support research into ibogaine, a Schedule I psychedelic drug, with the aim of potentially approving it for medical treatment, notably for PTSD and opioid addiction.
The executive order signed by President Donald Trump allocates $50 million for psychedelic research and streamlines the FDA review process for drugs like ibogaine. It extends the ‘Right to Try’ law to psychedelics, allowing terminal patients to access experimental treatments without full approval.
Several companies have submitted data for potential approval, and some are expected to be fast-tracked. The move follows lobbying from veterans’ groups and a notable involvement from figures like podcaster Joe Rogan, who facilitated communication with the White House.
Why It Matters
This development signifies a potential shift in U.S. drug policy, with increased federal support for psychedelic research and possible legalization. It could lead to new treatments for PTSD and opioid addiction, impacting public health and the war on drugs.
As an affiliate, we earn on qualifying purchases.
Background
Historically, psychedelics have been associated with counterculture and held Schedule I classification, indicating high potential for abuse and no accepted medical use. Recent years have seen growing bipartisan interest in their therapeutic potential, especially for mental health issues among veterans. The Trump administration’s move marks a notable departure from previous drug policies, reflecting changing attitudes toward psychedelics.
“The White House is now supporting increased research into psychedelics like ibogaine, especially for PTSD and addiction, which marks a significant shift in drug policy.”
— Mattha Busby, journalist
“I texted President Trump about psychedelics, and he responded almost instantly, indicating support for FDA approval.”
— Joe Rogan, podcast host
As an affiliate, we earn on qualifying purchases.
What Remains Unclear
It remains unclear whether the FDA will approve ibogaine or other psychedelics soon or what regulatory hurdles may still exist. The extent of actual legalization and widespread clinical use is still uncertain and depends on ongoing research outcomes. For more on related research, see My Favorite Bugs: Invalid Surrogate Pairs.
opioid addiction treatment supplements
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
What’s Next
Next steps include the allocation of funds for research, the submission of additional clinical trial data, and potential FDA decisions on approval. Monitoring congressional and regulatory developments will be key to understanding the future legal status of ibogaine.
As an affiliate, we earn on qualifying purchases.
Key Questions
What is ibogaine and how does it work?
Ibogaine is a psychedelic compound derived from the root bark of an African shrub, believed to help with opioid withdrawal and trauma recall, but it is also highly potent and potentially dangerous if misused.
Why is the Trump administration supporting this now?
Support appears driven by advocacy from veterans’ groups and figures like Joe Rogan, as well as a bipartisan shift toward exploring psychedelics for mental health treatment.
Could ibogaine become legally available for medical use?
It is possible if ongoing research demonstrates safety and efficacy, and if the FDA approves its use, but regulatory approval is not yet guaranteed.
What are the risks associated with ibogaine?
Ibogaine is known to be potent and can cause serious side effects, including heart problems and fatalities if used improperly. Its safety profile is still under investigation.
Source: Vox
Fall Picks
fall essentials
As an affiliate, we earn on qualifying purchases.
